Microneedling + Finasteride Stack (2026): Does Adding Microneedling Actually Help?

Last updated: June 2026 | Written by RK

Microneedling earned its place in the hair-loss conversation on the back of one landmark trial — Dhurat and colleagues’ 2013 study showing that weekly microneedling plus 5% topical minoxidil produced substantially better hair counts than minoxidil alone, in 100 men over 12 weeks [1]. That paper opened the question every reader of this article is asking: if microneedling boosts minoxidil, does it also boost topical finasteride?

The mechanistic answer is “almost certainly yes.” The clinical answer is more honest: the direct evidence for the microneedling + topical finasteride combination specifically is thin, but the closest analogue — microneedling + topical dutasteride — does have a small randomised trial showing benefit (Sánchez-Meza 2022) [2]. This guide walks through what we know, what we don’t, the practical protocol, and where the stack fits next to oral finasteride and topical finasteride monotherapy.

The mechanism: why the stack should work

Microneedling is not a hair-growth drug. It is a delivery and signalling intervention that combines two effects:

The growth-factor side and the delivery side are independent. Even if microneedling did nothing for drug penetration, the wound-healing growth factors alone might support follicle activity. Even if microneedling did nothing for growth factors, the enhanced penetration alone would push more topical fin into the right tissue compartment. Combining them is the mechanistic rationale for stacking.

For the underlying biology of microneedling specifically, see the dermaroller microneedling guide; for the topical-finasteride pharmacology, see topical finasteride for hair loss.

The evidence — what we actually have

The evidence base for stacking microneedling with 5α-reductase inhibitors has three pillars of varying strength.

The strongest pillar: microneedling + topical minoxidil (Dhurat 2013)

The foundational paper. Dhurat and colleagues randomised 100 men with androgenetic alopecia to weekly microneedling at 1.5 mm depth plus daily 5% topical minoxidil, vs daily 5% minoxidil alone, for 12 weeks [1]. The microneedling group showed:

• Greater increase in hair count at 12 weeks (mean +91.4 hairs/cm² vs +22.2 in the minoxidil-only arm — a roughly 4× difference).
• Greater patient-rated and investigator-rated improvement on standardised photographic assessment.
• A safety profile that was unremarkable beyond expected post-needling redness.

This is the trial the whole “stack” idea is built on. It is solid evidence for combining microneedling with topical minoxidil. The question is how much of that generalises.

The closest analogue: microneedling + topical dutasteride (Sánchez-Meza 2022)

Sánchez-Meza and colleagues at a Mexican dermatology centre ran a randomised placebo-controlled study of microneedling plus topical dutasteride solution vs microneedling plus placebo for androgenetic alopecia, published as a brief communication in JEADV in 2022 [2]. Dutasteride is the more potent sibling of finasteride — same drug class, broader 5α-reductase inhibition (see finasteride vs dutasteride).

The trial reported significant improvement in hair-density outcomes in the microneedling-plus-dutasteride arm compared with microneedling-plus-placebo. The sample is small and the paper is brief, but it is the single most direct piece of evidence that microneedling + topical 5α-reductase inhibition produces additional benefit over microneedling alone.

For the purposes of someone using topical finasteride, this dutasteride RCT is the closest indirect evidence available. The drugs share their mechanism; the conclusion plausibly applies.

The mechanistic generalisation: topical finasteride’s own evidence base

Topical finasteride has its own growing literature — Suchonwanit and colleagues’ 2022 review covered multiple small trials supporting its efficacy with substantially lower systemic exposure than oral finasteride [4]. Kumar and colleagues’ 2018 randomised single-observer-blinded study reproduced the direction of effect for the microneedling + topical minoxidil combo in a separate cohort [5].

What we are missing is a dedicated, large, placebo-controlled RCT specifically of microneedling + topical finasteride in AGA. Smaller trials and combination studies are emerging in 2023–2025, including a 2025 Chinese three-arm trial that included microneedling + minoxidil + finasteride, but the specific topical-fin stack does not yet have its own definitive trial.

The honest reading: the evidence is strong for combining microneedling with topical drugs in general, strong specifically for minoxidil, suggestive for dutasteride, and inferred-but-not-yet-proven for topical finasteride.

The protocol — what people actually do

Stitching together what the trials used and what dermatologists prescribing this stack typically recommend:

The two-step rationale: micro-channels in the upper barrier let more topical drug through, while growth factors released from the same micro-injuries support follicle activity. Two mechanisms, one protocol.

The systemic-absorption question

This is the question topical-finasteride users ask most often when considering microneedling. The honest answer:

• Yes, microneedling does increase how much of any topical drug reaches the dermis. That is its mechanism.
• For topical finasteride, that means more drug locally at the follicle (the point) and a small fraction more in systemic circulation.
• The relevant comparison is to oral finasteride, not to no treatment. Oral fin 1 mg/day produces ~60–70% scalp DHT suppression with substantial serum DHT effect. Topical fin produces meaningful scalp suppression with much smaller serum effect; adding microneedling shifts both numbers up modestly.
• For most users, the systemic shift is below the threshold where it would produce noticeable side effects. For users with prior finasteride sensitivity, the calculation is individual — see the finasteride side effects review and discuss with a dermatologist before stacking.

The practical framing: microneedling + topical fin still likely sits well below the systemic-exposure level of oral finasteride. If someone is choosing topical specifically because of side-effect concerns about oral, that calculation does not break by adding microneedling — it just nudges the dial.

Where this stack fits

How this stack compares to alternatives

Two honest comparisons:

• Microneedling + topical fin vs oral finasteride alone. Oral fin has 30+ years of randomised trial data (Kaufman 1998 phase III, multiple meta-analyses); the stack has Dhurat 2013 + Sánchez-Meza 2022 + the mechanistic generalisation. The stack is competitive on local effect; oral remains the standard for the strongest demonstrated systemic DHT suppression. Choosing between them is more about side-effect tolerance than about evidence ceiling — see finasteride vs dutasteride and the finasteride side effects guide.
• Microneedling + topical fin vs topical fin alone. Mechanistically there should be additional benefit; directly, the trial answering this question for finasteride specifically does not yet exist. The dutasteride RCT (Sánchez-Meza 2022) is the closest indirect support. A reasonable bet, not a proven one.

The honest verdict

The microneedling + finasteride stack sits in an interesting evidential position: strong mechanistic rationale, strong adjacent-trial support (microneedling + minoxidil, microneedling + dutasteride), and a small but growing direct literature for the exact topical-fin combination. It is the direction the field is moving but not yet anchored by a definitive trial.

For someone with progressing androgenetic alopecia who wants the most-aggressive topical-only approach, the stack is reasonable and increasingly mainstream in dermatology practice. For someone weighing it against oral finasteride, the choice is about side-effect tolerance more than about evidence ceiling. For someone newly starting treatment, build up in layers rather than starting with all three at once — track each addition with standardised photos and let the data tell you what is working.

What to read next

• Dermaroller / Microneedling Guide (2026) — the foundational evidence, devices, and technique for microneedling itself.
• Microneedling Results Timeline (2026) — what to expect month-by-month.
• Microneedling Infection Prevention (2026) — the safety guide; mandatory reading for at-home stacking.
• Topical Finasteride for Hair Loss (2026) — the drug half of the stack.
• Finasteride vs Dutasteride (2026) — context for the 5α-reductase-inhibitor decision.

References

[1] Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. “A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study.” Int J Trichology. 2013;5(1):6-11.

[2] Sánchez-Meza E, Ocampo-Candiani J, Gómez-Flores M, et al. “Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study.” J Eur Acad Dermatol Venereol. 2022;36(10):e806-e808.

[3] Aust MC, Reimers K, Repenning C, et al. “Percutaneous collagen induction: minimally invasive skin rejuvenation without risk of hyperpigmentation — fact or fiction?” Plast Reconstr Surg. 2008;122(5):1553-1563.

[4] Suchonwanit P, Iamsumang W, Rojhirunsakool S. “Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus Topical 3% Minoxidil Solution in the Treatment of Male Androgenetic Alopecia: A Randomized, Double-Blind, Controlled Study.” J Dermatolog Treat. 2022;33(2):643-648.

[5] Kumar MK, Inamadar AC, Palit A. “A Randomized Controlled, Single-Observer Blinded Study to Determine the Efficacy of Topical Minoxidil plus Microneedling versus Topical Minoxidil Alone in the Treatment of Androgenetic Alopecia.” J Cutan Aesthet Surg. 2018;11(4):211-216.

Disclaimer: This article is educational, not prescriptive. Microneedling at home requires sterile technique, and stacking it with topical 5α-reductase inhibitors is a protocol best supervised by a dermatologist — especially for anyone with prior finasteride sensitivity, immune compromise, scarring tendency, or atypical hair-loss presentation. Use this guide to inform a routine, not to replace a clinical conversation.